BioNexus Gene Lab Corp (BGLC) Financial Statements (2024 and earlier)

Company Profile

Business Address 10-2 TOWER B, VERTICAL BUSINESS SUITE,
KUALA LUMPUR, 59200
State of Incorp. WY
Fiscal Year End December 31
Industry (SIC) 8071 - Medical Laboratories (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2974076124784911,844
Cash and cash equivalents2974076124784911,844
Receivables5928325332
Inventory, net of allowances, customer advances and progress billings1,1669009781,0961,5121,649
Inventory1,1669009781,0961,5121,649
Asset, held-for-sale, not part of disposal group2,196     
Other undisclosed current assets1,5094,1254,4013,7823,7603,106
Total current assets:5,2275,4596,0225,4095,7666,601
Noncurrent Assets
Operating lease, right-of-use asset455156253136
Property, plant and equipment1,3971,4821,5121,4401,5331,628
Other undisclosed noncurrent assets1,2311,1951,1519241,039910
Total noncurrent assets:2,6722,7282,7182,3892,6032,574
TOTAL ASSETS:7,8998,1878,7407,7988,3699,175
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,8231,4941,8611,2791,4161,834
Accounts payable1,8231,4941,8611,2791,4161,834
Accrued liabilities      
Debt      21
Other undisclosed current liabilities54701435686129
Total current liabilities:1,8761,5632,0041,3351,5031,985
Noncurrent Liabilities
Long-term debt and lease obligation    141835
Finance lease, liability      13
Liabilities, other than long-term debt59667126  
Deferred income tax liabilities29313126  
Operating lease, liability303640141821
Other undisclosed noncurrent liabilities     97
Total noncurrent liabilities:596671404563
Total liabilities:1,9351,6302,0751,3751,5472,047
Equity
Equity, attributable to parent5,9646,5576,6656,4246,8227,128
Common stock10,93010,93010,93010,93010,93010,780
Additional paid in capital(5,012)(5,012)(5,012)(5,012)(5,012)(5,012)
Accumulated other comprehensive loss(782)(448)(409)(807)(487)(169)
Retained earnings (accumulated deficit)8281,0871,1561,3131,3911,529
Total equity:5,9646,5576,6656,4246,8227,128
TOTAL LIABILITIES AND EQUITY:7,8998,1878,7407,7988,3699,175

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues2,5672,3772,8402,5752,4853,029
Cost of revenue(2,227)(2,008)(2,500)(2,276)(2,242)(2,695)
Gross profit:340369339299243334
Operating expenses(807)(537)(488)(419)(434)(345)
Other undisclosed operating income19511726545346
Operating income (loss):(272)(51)(123)(65)(138)35
Nonoperating income (expense)
(loss, Foreign Currency Transaction, before Tax)
      (69)
Interest and debt expense  (2)    
Loss from continuing operations before equity method investments, income taxes:(272)(53)(123)(65)(138)(34)
Other undisclosed loss from continuing operations before income taxes(3) (5)(2)(2) 
Loss from continuing operations before income taxes:(275)(53)(127)(67)(140)(34)
Income tax expense (benefit)(16)(16)75(10)2(14)
Loss from continuing operations:(291)(69)(52)(77)(139)(48)
Loss before gain (loss) on sale of properties:(77)(139)(48)
Other undisclosed net income (loss)   (105)  31
Net loss:(291)(69)(157)(77)(139)(17)
Other undisclosed net income attributable to parent 32    34
Net income (loss) available to common stockholders, diluted:(259)(69)(157)(77)(139)17

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(291)(69)(157)(77)(139)(17)
Comprehensive loss:(291)(69)(157)(77)(139)(17)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(302)(39)398(321)(318)(35)
Comprehensive income (loss), net of tax, attributable to parent:(593)(108)241(398)(456)(52)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: